lamotrigine has been researched along with Dementia Praecox in 56 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Several placebo controlled studies investigating lamotrigine augmentation of clozapine in schizophrenia patients with partial response have shown varying results." | 9.17 | Lamotrigine augmentation in patients with schizophrenia who show partial response to clozapine treatment. ( Anıl Yağcıoğlu, AE; Gürel, SC; Karahan, S; Karcı, O; Vayısoğlu, S; Yağcıoğlu, S; Yazıcı, MK, 2013) |
| "Augmenting antipsychotics with the mood stabilizers of lamotrigine or divalproex sodium for most partially responsive patients with chronic schizophrenia did not seem to be a useful treatment strategy for improving the residual symptoms." | 9.14 | A double-blind randomized trial of mood stabilizer augmentation using lamotrigine and valproate for patients with schizophrenia who are stabilized and partially responsive. ( Bosch, J; Casey, DE; Glick, ID, 2009) |
| ": Two multicenter, randomized, double-blind, 12-week, parallel-group trials were conducted to compare flexibly dosed lamotrigine (100-400 mg/d) with placebo as add-on treatment in schizophrenia patients with stable, residual psychotic symptoms." | 9.12 | Lamotrigine as add-on therapy in schizophrenia: results of 2 placebo-controlled trials. ( Citrome, L; Davy, K; Goff, DC; Keefe, R; Krystal, JH; Large, C; Thompson, TR; Volavka, J; Webster, EL, 2007) |
| "The effect of lamotrigine on the steady-state plasma concentrations of the atypical antipsychotics clozapine, olanzapine, and risperidone was investigated in patients with schizophrenia or bipolar disorder stabilized on chronic treatment with clozapine (200-500 mg/day; n = 11), risperidone (3-6 mg/day; n = 10) or olanzapine (10-20 mg/day; n = 14))." | 9.12 | Effect of adjunctive lamotrigine treatment on the plasma concentrations of clozapine, risperidone and olanzapine in patients with schizophrenia or bipolar disorder. ( D'Amico, G; D'Arrigo, C; Micò, U; Migliardi, G; Muscatello, MR; Perucca, E; Santoro, V; Spina, E, 2006) |
| "These preliminary findings 1) support the hypothesis that lamotrigine adjuvant treatment may improve positive symptoms and general psychopathology in schizophrenia, 2) suggest that beneficial effects may be achieved when lamotrigine is added to both conventional and atypical antipsychotics, and 3) warrant additional, larger scale trials." | 9.11 | Placebo-controlled trial of lamotrigine added to conventional and atypical antipsychotics in schizophrenia. ( Bar, G; Blanaru, M; Gorelik, I; Heresco-Levy, U; Javitt, DC; Kremer, I; Vass, A, 2004) |
| "Thirty-four hospitalized treatment-resistant patients having chronic schizophrenia participated in a double-blind, placebo-controlled, 14-week, crossover trial where 200 mg/day lamotrigine was gradually added to their ongoing clozapine treatment." | 9.10 | Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled crossover trial. ( Eronen, M; Hallikainen, T; Kotilainen, I; Putkonen, A; Repo-Tiihonen, E; Ryynänen, OP; Tiihonen, J; Toivonen, P; Wahlbeck, K, 2003) |
| "When schizophrenia patients have insufficient response to clozapine, pharmacological augmentation is often applied." | 8.88 | Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review. ( Begemann, MJ; Leucht, S; Sommer, IE; Temmerman, A, 2012) |
| "This meta-analysis suggests that lamotrigine augmentation may be an effective treatment for patients with clozapine-resistant schizophrenia." | 8.85 | The efficacy of lamotrigine in clozapine-resistant schizophrenia: a systematic review and meta-analysis. ( Kiviniemi, V; Tiihonen, J; Wahlbeck, K, 2009) |
| "To evaluate the effects of adjuvant lamotrigine for people with schizophrenia and schizophrenia-like psychoses." | 8.83 | Lamotrigine for schizophrenia. ( Pick, J; Premkumar, TS, 2006) |
| "Data from four clinical studies support the efficacy of adjunctive lamotrigine in the treatment of schizophrenia." | 8.82 | The potential role of lamotrigine in schizophrenia. ( Goff, DC; Large, CH; Webster, EL, 2005) |
| "Findings indicate that alterations in dopamine neurotransmission, glutamate metabolism, and GABA signaling may contribute to some of the behavioral deficits observed following PCP-SI, and that lamotrigine may have some utility as an adjunctive therapy to improve certain cognitive deficits symptoms in schizophrenia." | 7.83 | Down-Regulation of Hippocampal Genes Regulating Dopaminergic, GABAergic, and Glutamatergic Function Following Combined Neonatal Phencyclidine and Post-Weaning Social Isolation of Rats as a Neurodevelopmental Model for Schizophrenia. ( Alexander, SP; Fone, KC; Gaskin, PL; Toledo-Rodriguez, M, 2016) |
| "Stevens-Johnson syndrome is a severe and potentially life-threatening cutaneous reaction associated with lamotrigine." | 7.74 | Concomitant use of lamotrigine and aripiprazole increases risk of Stevens-Johnson syndrome? ( Chen, CH; Chen, SJ; Lin, CC; Shen, YC, 2007) |
| "Lamotrigine has a modulating effect on glutamatergic neurotransmission relevant to pathophysiology of both schizophrenia and OCD." | 6.75 | Lamotrigine augmentation in schizophrenia and schizoaffective patients with obsessive-compulsive symptoms. ( Glick, I; Koran, LM; Poyurovsky, M, 2010) |
| "Periodic catatonia is a rare form of catatonia, characterized by episodes occurring in a cyclic pattern with clinical features of combined stupor and excitement, with intervals of remission." | 5.62 | Periodic Catatonia: Long-term Treatment With Lamotrigine: A Case Report. ( Angelopoulos, E; Konstantinou, G; Papageorgiou, CC, 2021) |
| "Comorbid alcohol dependence is common in patients with schizophrenia and is associated with a variety of serious adverse consequences." | 5.33 | Use of lamotrigine to augment clozapine in patients with resistant schizophrenia and comorbid alcohol dependence: a potent anti-craving effect? ( Beyazyürek, M; Kalyoncu, A; Mirsal, H; Pektas, O; Tan, D; Unsalan, N, 2005) |
| "Several placebo controlled studies investigating lamotrigine augmentation of clozapine in schizophrenia patients with partial response have shown varying results." | 5.17 | Lamotrigine augmentation in patients with schizophrenia who show partial response to clozapine treatment. ( Anıl Yağcıoğlu, AE; Gürel, SC; Karahan, S; Karcı, O; Vayısoğlu, S; Yağcıoğlu, S; Yazıcı, MK, 2013) |
| "Augmenting antipsychotics with the mood stabilizers of lamotrigine or divalproex sodium for most partially responsive patients with chronic schizophrenia did not seem to be a useful treatment strategy for improving the residual symptoms." | 5.14 | A double-blind randomized trial of mood stabilizer augmentation using lamotrigine and valproate for patients with schizophrenia who are stabilized and partially responsive. ( Bosch, J; Casey, DE; Glick, ID, 2009) |
| "The effect of lamotrigine on the steady-state plasma concentrations of the atypical antipsychotics clozapine, olanzapine, and risperidone was investigated in patients with schizophrenia or bipolar disorder stabilized on chronic treatment with clozapine (200-500 mg/day; n = 11), risperidone (3-6 mg/day; n = 10) or olanzapine (10-20 mg/day; n = 14))." | 5.12 | Effect of adjunctive lamotrigine treatment on the plasma concentrations of clozapine, risperidone and olanzapine in patients with schizophrenia or bipolar disorder. ( D'Amico, G; D'Arrigo, C; Micò, U; Migliardi, G; Muscatello, MR; Perucca, E; Santoro, V; Spina, E, 2006) |
| ": Two multicenter, randomized, double-blind, 12-week, parallel-group trials were conducted to compare flexibly dosed lamotrigine (100-400 mg/d) with placebo as add-on treatment in schizophrenia patients with stable, residual psychotic symptoms." | 5.12 | Lamotrigine as add-on therapy in schizophrenia: results of 2 placebo-controlled trials. ( Citrome, L; Davy, K; Goff, DC; Keefe, R; Krystal, JH; Large, C; Thompson, TR; Volavka, J; Webster, EL, 2007) |
| "These preliminary findings 1) support the hypothesis that lamotrigine adjuvant treatment may improve positive symptoms and general psychopathology in schizophrenia, 2) suggest that beneficial effects may be achieved when lamotrigine is added to both conventional and atypical antipsychotics, and 3) warrant additional, larger scale trials." | 5.11 | Placebo-controlled trial of lamotrigine added to conventional and atypical antipsychotics in schizophrenia. ( Bar, G; Blanaru, M; Gorelik, I; Heresco-Levy, U; Javitt, DC; Kremer, I; Vass, A, 2004) |
| "Thirty-four hospitalized treatment-resistant patients having chronic schizophrenia participated in a double-blind, placebo-controlled, 14-week, crossover trial where 200 mg/day lamotrigine was gradually added to their ongoing clozapine treatment." | 5.10 | Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled crossover trial. ( Eronen, M; Hallikainen, T; Kotilainen, I; Putkonen, A; Repo-Tiihonen, E; Ryynänen, OP; Tiihonen, J; Toivonen, P; Wahlbeck, K, 2003) |
| "When schizophrenia patients have insufficient response to clozapine, pharmacological augmentation is often applied." | 4.88 | Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review. ( Begemann, MJ; Leucht, S; Sommer, IE; Temmerman, A, 2012) |
| "Clozapine treatment remains the gold standard for treatment-resistant schizophrenia, but treatment with clozapine is associated with several side-effects that complicate the use of the drug." | 4.87 | Optimizing clozapine treatment. ( Damkier, P; Lublin, H; Nielsen, J; Taylor, D, 2011) |
| "This meta-analysis suggests that lamotrigine augmentation may be an effective treatment for patients with clozapine-resistant schizophrenia." | 4.85 | The efficacy of lamotrigine in clozapine-resistant schizophrenia: a systematic review and meta-analysis. ( Kiviniemi, V; Tiihonen, J; Wahlbeck, K, 2009) |
| "To evaluate the effects of adjuvant lamotrigine for people with schizophrenia and schizophrenia-like psychoses." | 4.83 | Lamotrigine for schizophrenia. ( Pick, J; Premkumar, TS, 2006) |
| "Data from four clinical studies support the efficacy of adjunctive lamotrigine in the treatment of schizophrenia." | 4.82 | The potential role of lamotrigine in schizophrenia. ( Goff, DC; Large, CH; Webster, EL, 2005) |
| "We found increased risks of cataract development in long-term users of lithium, lithium combined with other MS and valproic acid combined with other MS for more than two years among patients with BD and schizophrenia." | 3.88 | Associations between use of mood stabilizers and risk of cataract: A population-based nested case-control study. ( Chou, PH; Chu, CS; Lan, TH; Lin, CH, 2018) |
| "Findings indicate that alterations in dopamine neurotransmission, glutamate metabolism, and GABA signaling may contribute to some of the behavioral deficits observed following PCP-SI, and that lamotrigine may have some utility as an adjunctive therapy to improve certain cognitive deficits symptoms in schizophrenia." | 3.83 | Down-Regulation of Hippocampal Genes Regulating Dopaminergic, GABAergic, and Glutamatergic Function Following Combined Neonatal Phencyclidine and Post-Weaning Social Isolation of Rats as a Neurodevelopmental Model for Schizophrenia. ( Alexander, SP; Fone, KC; Gaskin, PL; Toledo-Rodriguez, M, 2016) |
| "Stevens-Johnson syndrome is a severe and potentially life-threatening cutaneous reaction associated with lamotrigine." | 3.74 | Concomitant use of lamotrigine and aripiprazole increases risk of Stevens-Johnson syndrome? ( Chen, CH; Chen, SJ; Lin, CC; Shen, YC, 2007) |
| "Lamotrigine has a modulating effect on glutamatergic neurotransmission relevant to pathophysiology of both schizophrenia and OCD." | 2.75 | Lamotrigine augmentation in schizophrenia and schizoaffective patients with obsessive-compulsive symptoms. ( Glick, I; Koran, LM; Poyurovsky, M, 2010) |
| "Periodic catatonia is a rare form of catatonia, characterized by episodes occurring in a cyclic pattern with clinical features of combined stupor and excitement, with intervals of remission." | 1.62 | Periodic Catatonia: Long-term Treatment With Lamotrigine: A Case Report. ( Angelopoulos, E; Konstantinou, G; Papageorgiou, CC, 2021) |
| "Lamotrigine can cause pneumonitis, and this side effect should be suspected in patients who are being treated with lamotrigine and presenting with progressive dyspnoea." | 1.43 | [Lamotrigine-induced pneumonitis]. ( Davidsen, JR; Madsen, HD, 2016) |
| "Comorbid alcohol dependence is common in patients with schizophrenia and is associated with a variety of serious adverse consequences." | 1.33 | Use of lamotrigine to augment clozapine in patients with resistant schizophrenia and comorbid alcohol dependence: a potent anti-craving effect? ( Beyazyürek, M; Kalyoncu, A; Mirsal, H; Pektas, O; Tan, D; Unsalan, N, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (1.79) | 18.2507 |
| 2000's | 35 (62.50) | 29.6817 |
| 2010's | 17 (30.36) | 24.3611 |
| 2020's | 3 (5.36) | 2.80 |
| Authors | Studies |
|---|---|
| Abram, SV | 1 |
| Roach, BJ | 1 |
| Fryer, SL | 1 |
| Calhoun, VD | 1 |
| Preda, A | 1 |
| van Erp, TGM | 1 |
| Bustillo, JR | 1 |
| Lim, KO | 1 |
| Loewy, RL | 1 |
| Stuart, BK | 1 |
| Krystal, JH | 4 |
| Ford, JM | 1 |
| Mathalon, DH | 1 |
| Puranen, A | 1 |
| Koponen, M | 1 |
| Lähteenvuo, M | 1 |
| Tanskanen, A | 1 |
| Tiihonen, J | 4 |
| Taipale, H | 1 |
| Tsai, LH | 1 |
| Lin, JW | 1 |
| Konstantinou, G | 1 |
| Papageorgiou, CC | 1 |
| Angelopoulos, E | 1 |
| Chu, CS | 1 |
| Lin, CH | 1 |
| Lan, TH | 1 |
| Chou, PH | 1 |
| McCain, CF | 1 |
| Namey, LB | 1 |
| Freudenreich, O | 1 |
| Peretti, CS | 1 |
| Chouinard, G | 2 |
| Legrand, G | 1 |
| May, R | 1 |
| Richard, B | 1 |
| Kernisant, M | 1 |
| Jalenques, I | 1 |
| Ohnuma, T | 1 |
| Takebayashi, Y | 1 |
| Higashiyama, R | 1 |
| Shibata, N | 1 |
| Arai, H | 1 |
| Goff, DC | 3 |
| Szmulewicz, AG | 1 |
| Valerio, MP | 1 |
| Smith, JM | 1 |
| Gaskin, PL | 1 |
| Toledo-Rodriguez, M | 1 |
| Alexander, SP | 1 |
| Fone, KC | 1 |
| Madsen, HD | 1 |
| Davidsen, JR | 1 |
| Poyurovsky, M | 1 |
| Glick, I | 1 |
| Koran, LM | 1 |
| Wahlbeck, K | 3 |
| Kiviniemi, V | 1 |
| Glick, ID | 1 |
| Bosch, J | 1 |
| Casey, DE | 1 |
| Citrome, L | 2 |
| Nakato, Y | 1 |
| Abekawa, T | 1 |
| Ito, K | 1 |
| Inoue, T | 1 |
| Koyama, T | 1 |
| Ventriglio, A | 1 |
| Vincenti, A | 1 |
| Centorrino, F | 1 |
| Talamo, A | 1 |
| Fitzmaurice, G | 1 |
| Baldessarini, RJ | 1 |
| Sommer, IE | 1 |
| Begemann, MJ | 1 |
| Temmerman, A | 1 |
| Leucht, S | 1 |
| Nielsen, J | 1 |
| Damkier, P | 1 |
| Lublin, H | 1 |
| Taylor, D | 1 |
| Gazdag, G | 1 |
| Takács, R | 1 |
| Ungvari, GS | 1 |
| Vayısoğlu, S | 1 |
| Anıl Yağcıoğlu, AE | 1 |
| Yağcıoğlu, S | 1 |
| Karahan, S | 1 |
| Karcı, O | 1 |
| Gürel, SC | 1 |
| Yazıcı, MK | 1 |
| Kalkman, HO | 1 |
| Hosák, L | 1 |
| Libiger, J | 1 |
| Hallikainen, T | 2 |
| Ryynänen, OP | 2 |
| Repo-Tiihonen, E | 2 |
| Kotilainen, I | 2 |
| Eronen, M | 2 |
| Toivonen, P | 2 |
| Putkonen, A | 2 |
| Brody, SA | 1 |
| Conquet, F | 1 |
| Geyer, MA | 1 |
| Stuve, W | 1 |
| Wessels, A | 1 |
| Timmerman, L | 1 |
| Kolivakis, TT | 1 |
| Beauclair, L | 1 |
| Margolese, HC | 1 |
| Stahl, SM | 1 |
| Holzer, L | 1 |
| Halfon, O | 1 |
| Kremer, I | 1 |
| Vass, A | 1 |
| Gorelik, I | 1 |
| Bar, G | 1 |
| Blanaru, M | 1 |
| Javitt, DC | 2 |
| Heresco-Levy, U | 2 |
| Bienentreu, SD | 1 |
| Kronmüller, KT | 1 |
| Kalyoncu, A | 1 |
| Mirsal, H | 1 |
| Pektas, O | 1 |
| Unsalan, N | 1 |
| Tan, D | 1 |
| Beyazyürek, M | 1 |
| Large, CH | 1 |
| Webster, EL | 2 |
| Thomas, R | 1 |
| Howe, V | 1 |
| Foister, K | 1 |
| Keks, N | 1 |
| Chan, YC | 1 |
| Miller, KM | 1 |
| Shaheen, N | 1 |
| Votolato, NA | 1 |
| Hankins, MB | 1 |
| Heck, AH | 1 |
| de Groot, IW | 1 |
| van Harten, PN | 1 |
| Spina, E | 2 |
| D'Arrigo, C | 1 |
| Migliardi, G | 1 |
| Santoro, V | 1 |
| Muscatello, MR | 2 |
| Micò, U | 2 |
| D'Amico, G | 1 |
| Perucca, E | 1 |
| Premkumar, TS | 1 |
| Pick, J | 1 |
| Llorca, PM | 1 |
| Zoccali, R | 1 |
| Bruno, A | 1 |
| Cambria, R | 1 |
| Meduri, M | 1 |
| Shen, YC | 1 |
| Chen, SJ | 1 |
| Lin, CC | 1 |
| Chen, CH | 1 |
| Cilia, J | 1 |
| Hatcher, P | 1 |
| Reavill, C | 1 |
| Jones, DN | 1 |
| Keefe, R | 1 |
| Davy, K | 1 |
| Large, C | 1 |
| Thompson, TR | 1 |
| Volavka, J | 1 |
| Moeller, KE | 1 |
| Wei, L | 1 |
| Jewell, AD | 1 |
| Carver, LA | 1 |
| Dursun, SM | 3 |
| McIntosh, D | 1 |
| Milliken, H | 1 |
| Anand, A | 2 |
| Charney, DS | 1 |
| Oren, DA | 1 |
| Berman, RM | 1 |
| Hu, XS | 1 |
| Cappiello, A | 1 |
| Devarajan, S | 1 |
| Kossen, M | 1 |
| Selten, JP | 1 |
| Kahn, RS | 1 |
| Deakin, JF | 1 |
| Saba, G | 1 |
| Dumortier, G | 1 |
| Kalalou, K | 1 |
| Benadhira, R | 1 |
| Degrassat, K | 1 |
| Glikman, J | 1 |
| Januel, D | 1 |
| Shim, SS | 1 |
| Moghaddam, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase IIA, Prospective, Randomized, Double-blind, Multiple-dose Study of NW-3509A in Chronic Schizoprhenia Patients Not Responding to Their Current Anti-psychotic Medication[NCT02624167] | Phase 2 | 90 participants (Actual) | Interventional | 2015-12-31 | Completed | ||
| Minocycline Augmentation of Clozapine for Treatment Resistant Schizophrenia: A Randomised Placebo-controlled Double-blind Trial[NCT02533232] | Phase 1 | 60 participants (Anticipated) | Interventional | 2022-08-30 | Recruiting | ||
| L-Arginine add-on Treatment for Schizophrenia: A Randomized, Double Blind, Placebo Controlled, Cross Over Study[NCT02398279] | 12 participants (Actual) | Interventional | 2011-06-30 | Completed | |||
| A Multi-Center, Double Blind, Placebo-controlled, Randomized, Parallel Group Evaluation of the Efficacy of a Flexible Dose of Lamotrigine Versus Placebo As Add-On Therapy In Schizophrenia[NCT00071747] | Phase 3 | 176 participants | Interventional | 2003-08-31 | Completed | ||
| An Investigation of the Antidepressant Efficacy and Safety of an AMPAkine (Org 24448) in Major Depressive Disorder, A Double-Blind, Placebo-Controlled, Randomized Study[NCT00113022] | Phase 2 | 9 participants (Actual) | Interventional | 2005-05-31 | Terminated (stopped due to Terminated due to concerns about adverse events in separate study.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The MADRS is a measure of depression severity examined on a weekly basis. The minimum score on the 10 item scale is 0 indicating no depression. The maximum score is 60 indicating a very severe depression. Scores of 18 and above are generally considered to suggest significant levels of depression. (NCT00113022)
Timeframe: 8 weeks
| Intervention | Scores on a scale (Least Squares Mean) |
|---|---|
| Org 24448 | 26.425 |
| Placebo | 24.205 |
11 reviews available for lamotrigine and Dementia Praecox
| Article | Year |
|---|---|
Drug development in schizophrenia: are glutamatergic targets still worth aiming at?
Topics: Excitatory Amino Acid Agents; Glutamic Acid; Humans; Lamotrigine; Receptors, AMPA; Receptors, Metabo | 2015 |
The efficacy of lamotrigine in clozapine-resistant schizophrenia: a systematic review and meta-analysis.
Topics: Age Factors; Anticonvulsants; Antipsychotic Agents; Clozapine; Cognition Disorders; Drug Resistance; | 2009 |
Adding lithium or anticonvulsants to antipsychotics for the treatment of schizophrenia: useful strategy or exercise in futility?
Topics: Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Delayed-Action Preparations; Drug Therapy, | 2009 |
Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review.
Topics: Antipsychotic Agents; Brief Psychiatric Rating Scale; Citalopram; Clozapine; Dioxoles; Double-Blind | 2012 |
Optimizing clozapine treatment.
Topics: Antipsychotic Agents; Calcium Channel Blockers; Central Nervous System Diseases; Clozapine; Combined | 2011 |
[The optimal combination of ECT with pharmacotherapy].
Topics: Affect; Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tric | 2011 |
Antischizophrenic activity independent of dopamine D2 blockade.
Topics: Amino Acid Transport System X-AG; Animals; Antipsychotic Agents; Brain Chemistry; Dopamine D2 Recept | 2002 |
Antiepileptic drugs in schizophrenia: a review.
Topics: Anticonvulsants; Antipsychotic Agents; Carbamazepine; Drug Resistance; Humans; Lamotrigine; Receptor | 2002 |
The potential role of lamotrigine in schizophrenia.
Topics: Animals; Anticonvulsants; Antipsychotic Agents; Brain; Disease Models, Animal; Drug Synergism; Drug | 2005 |
Lamotrigine for schizophrenia.
Topics: Antipsychotic Agents; Chemotherapy, Adjuvant; Humans; Lamotrigine; Randomized Controlled Trials as T | 2006 |
[Non-dopaminergic drugs in schizophrenia].
Topics: Animals; Anticonvulsants; Antipsychotic Agents; Brain; Dopamine Antagonists; Drug Resistance; Humans | 2006 |
15 trials available for lamotrigine and Dementia Praecox
| Article | Year |
|---|---|
Validation of ketamine as a pharmacological model of thalamic dysconnectivity across the illness course of schizophrenia.
Topics: Glutamates; Hallucinations; Humans; Ketamine; Lamotrigine; Magnetic Resonance Imaging; Receptors, N- | 2022 |
Lamotrigine augmentation in schizophrenia and schizoaffective patients with obsessive-compulsive symptoms.
Topics: Adolescent; Adult; Antimanic Agents; Antipsychotic Agents; Compulsive Behavior; Drug Administration | 2010 |
A double-blind randomized trial of mood stabilizer augmentation using lamotrigine and valproate for patients with schizophrenia who are stabilized and partially responsive.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combination; Femal | 2009 |
Lamotrigine augmentation in patients with schizophrenia who show partial response to clozapine treatment.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antipsychotic Agents; Calcium Channel Blockers; Chi-S | 2013 |
Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled crossover trial.
Topics: Adult; Cross-Over Studies; Double-Blind Method; Drug Resistance; Excitatory Amino Acid Antagonists; | 2003 |
[Lamotrigine in clozapine treatment-resistant schizophrenia].
Topics: Antipsychotic Agents; Clozapine; Drug Resistance; Drug Therapy, Combination; Female; Follow-Up Studi | 2004 |
Long-term lamotrigine adjunctive to antipsychotic monotherapy in schizophrenia: further evidence.
Topics: Adult; Antipsychotic Agents; Female; Humans; Lamotrigine; Male; Middle Aged; Outcome Assessment, Hea | 2004 |
Placebo-controlled trial of lamotrigine added to conventional and atypical antipsychotics in schizophrenia.
Topics: Adult; Amino Acids; Anticonvulsants; Antipsychotic Agents; Behavioral Symptoms; Double-Blind Method; | 2004 |
Addition of lamotrigine to clozapine in inpatients with chronic psychosis.
Topics: Anticonvulsants; Antipsychotic Agents; Clozapine; Drug Therapy, Combination; Humans; Lamotrigine; Mi | 2005 |
Effect of adjunctive lamotrigine treatment on the plasma concentrations of clozapine, risperidone and olanzapine in patients with schizophrenia or bipolar disorder.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Clozapine; Drug Interactions; Female | 2006 |
The effect of lamotrigine augmentation of clozapine in a sample of treatment-resistant schizophrenic patients: a double-blind, placebo-controlled study.
Topics: Adult; Anticonvulsants; Antipsychotic Agents; Attention; Brief Psychiatric Rating Scale; Clozapine; | 2007 |
Lamotrigine as add-on therapy in schizophrenia: results of 2 placebo-controlled trials.
Topics: Adult; Anticonvulsants; Antipsychotic Agents; Clozapine; Diagnostic and Statistical Manual of Mental | 2007 |
Clozapine plus lamotrigine in treatment-resistant schizophrenia.
Topics: Adult; Ambulatory Care; Anticonvulsants; Antipsychotic Agents; Clozapine; Female; Humans; Lamotrigin | 1999 |
Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists.
Topics: Adult; Affect; Brief Psychiatric Rating Scale; Cognition Disorders; Double-Blind Method; Excitatory | 2000 |
Augmenting antipsychotic treatment with lamotrigine or topiramate in patients with treatment-resistant schizophrenia: a naturalistic case-series outcome study.
Topics: Adult; Antipsychotic Agents; Clozapine; Drug Resistance; Drug Therapy, Combination; Excitatory Amino | 2001 |
30 other studies available for lamotrigine and Dementia Praecox
| Article | Year |
|---|---|
Real-world effectiveness of mood stabilizer use in schizophrenia.
Topics: Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Carbamazepine; Female; Humans; Lamotrigine; | 2023 |
Use of clozapine for resolving lamotrigine-induced skin lesions caused by schizophrenia treatment.
Topics: Adult; Antipsychotic Agents; Clozapine; Exanthema; Female; Humans; Lamotrigine; Schizophrenia | 2019 |
Periodic Catatonia: Long-term Treatment With Lamotrigine: A Case Report.
Topics: Catatonia; Hospitalization; Humans; Lamotrigine; Long-Term Care; Schizophrenia | 2021 |
Associations between use of mood stabilizers and risk of cataract: A population-based nested case-control study.
Topics: Adult; Aged; Antimanic Agents; Bipolar Disorder; Carbamazepine; Case-Control Studies; Cataract; Data | 2018 |
Lamotrigine Cross-Reactivity With Phencyclidine in Rapid Urine Toxicology in a Research Study.
Topics: Adult; Antipsychotic Agents; Clinical Trials as Topic; False Positive Reactions; Female; Humans; Imm | 2018 |
Aripiprazole Combined with Lamotrigine in the Treatment of a Treatment-Resistant Schizophrenic Patient with Tardive Dyskinesia and Supersensitivity Psychosis.
Topics: Antipsychotic Agents; Aripiprazole; Drug Resistance; Drug Therapy, Combination; Humans; Lamotrigine; | 2019 |
A case report of partial bowel obstruction after aripiprazole addition to clozapine in a young male with schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Defecation; Drug Substitution; Drug Therapy, C | 2013 |
Low-dose lamotrigine augmentation therapy improves residual symptoms in treatment-resistant schizophrenia: a report of five cases.
Topics: Adult; Anticonvulsants; Antipsychotic Agents; Dose-Response Relationship, Drug; Drug Synergism; Drug | 2013 |
Obsessive-compulsive symptoms in adjunctive therapy with lamotrigine in clozapine-medicated patients.
Topics: Adult; Antipsychotic Agents; Clozapine; Cross-Sectional Studies; Drug Therapy, Combination; Female; | 2015 |
Down-Regulation of Hippocampal Genes Regulating Dopaminergic, GABAergic, and Glutamatergic Function Following Combined Neonatal Phencyclidine and Post-Weaning Social Isolation of Rats as a Neurodevelopmental Model for Schizophrenia.
Topics: Animals; Animals, Newborn; Behavior, Animal; Disease Models, Animal; Dopaminergic Neurons; GABAergic | 2016 |
[Lamotrigine-induced pneumonitis].
Topics: Adult; Anticonvulsants; Female; Forced Expiratory Volume; Humans; Lamotrigine; Pneumonia; Schizophre | 2016 |
Lamotrigine blocks the initiation and expression of repeated high-dose methamphetamine-induced prepulse inhibition deficit in rats.
Topics: Animals; Anticonvulsants; Central Nervous System Stimulants; Disease Models, Animal; Lamotrigine; Ma | 2010 |
Use of mood stabilizers for hospitalized psychotic and bipolar disorder patients.
Topics: Anticonvulsants; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Dr | 2011 |
Disruption of prepulse inhibition in mice lacking mGluR1.
Topics: Acoustic Stimulation; Animals; Antimanic Agents; Brain; Disease Models, Animal; Dopamine Antagonists | 2003 |
Remission of positive symptomatology of a schizophrenic psychosis after withdrawing lamotrigine: a case report.
Topics: Adult; Antimanic Agents; Humans; Lamotrigine; Male; Psychotic Disorders; Remission, Spontaneous; Sch | 2004 |
Anticonvulsants as mood stabilizers and adjuncts to antipsychotics: valproate, lamotrigine, carbamazepine, and oxcarbazepine and actions at voltage-gated sodium channels.
Topics: Affect; Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Carbamazepine; Drug Therapy, Combin | 2004 |
Normalization of impaired cognitive functions failed to improve clinical symptomatology in a schizophrenic patient.
Topics: Acute Disease; Adolescent; Antipsychotic Agents; Benzodiazepines; Brain; Cognition Disorders; Electr | 2004 |
Increase in risperidone plasma level with lamotrigine.
Topics: Adult; Anticonvulsants; Antipsychotic Agents; Drug Interactions; Drug Therapy, Combination; Female; | 2005 |
Use of lamotrigine to augment clozapine in patients with resistant schizophrenia and comorbid alcohol dependence: a potent anti-craving effect?
Topics: Adult; Alcoholism; Antimanic Agents; Antipsychotic Agents; Clozapine; Diagnosis, Dual (Psychiatry); | 2005 |
Adjunctive lamotrigine in treatment-resistant schizophrenia.
Topics: Adult; Anticonvulsants; Antipsychotic Agents; Drug Resistance; Drug Therapy, Combination; Female; Hu | 2006 |
Worsening of psychotic symptoms in schizophrenia with addition of lamotrigine: a case report.
Topics: Adult; Antipsychotic Agents; Brain; Clozapine; Drug Therapy, Combination; Female; Humans; Lamotrigin | 2005 |
Concomitant use of lamotrigine and aripiprazole increases risk of Stevens-Johnson syndrome?
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Drug Therapy, Combination; Female; Huma | 2007 |
(+/-) Ketamine-induced prepulse inhibition deficits of an acoustic startle response in rats are not reversed by antipsychotics.
Topics: Animals; Antipsychotic Agents; Clozapine; Dose-Response Relationship, Drug; Excitatory Amino Acid An | 2007 |
Acute hepatotoxicity associated with lamotrigine.
Topics: Adult; Anticonvulsants; Humans; Lamotrigine; Liver Failure, Acute; Male; Schizophrenia; Triazines | 2008 |
Are glycine sites saturated in vivo?
Topics: Anticonvulsants; Antipsychotic Agents; Humans; Lamotrigine; Receptors, Glycine; Receptors, N-Methyl- | 2000 |
When treating patients with schizophrenia, what clinical points should be considered if lamotrigine is chosen to augment clozapine?
Topics: Antipsychotic Agents; Clozapine; Drug Administration Schedule; Drug Therapy, Combination; Humans; La | 2001 |
Elevated clozapine plasma level with lamotrigine.
Topics: Adult; Anticonvulsants; Antipsychotic Agents; Clozapine; Drug Therapy, Combination; Humans; Lamotrig | 2001 |
Lamotrigine--clozapine combination in refractory schizophrenia: three cases.
Topics: Adult; Anticonvulsants; Antipsychotic Agents; Clozapine; Drug Resistance; Drug Therapy, Combination; | 2002 |
Is NMDA receptor hypofunction in schizophrenia associated with a primary hyperglutamatergic state?
Topics: Excitatory Amino Acid Antagonists; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Ketamine; Lamotri | 2002 |
Effects of NMDA receptor antagonists: implications for the pathophysiology of schizophrenia.
Topics: Animals; Dopamine; Glutamates; Humans; Ketamine; Lamotrigine; Models, Animal; Phencyclidine; Prefron | 2002 |